In this article, Mark Copley, Chief Executive Officer, Copley Scientific, considers cascade impaction as a method for determining the aerodynamic particle size distribution of orally inhaled drug products, and how techniques to improve air flow control and semi-automation of the process can significantly reduce the variability involved.
This article was taken from ONdrugDelivery December 2018.© 2024 Frederick Furness Publishing.